Early insights into viability of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak
Genomic and structural analyses of the 2026 Bundibugyo virus outbreak suggest that while the mAb114 therapy may be compromised by specific mutations, the MBP134 cocktail remains a promising broadly protective option and the Inmazeb trimeric cocktail retains efficacy through synergistic binding, highlighting the critical need for urgent experimental validation.